BIOGEN INC. Non Peo Neo Avg Total Comp Amt
BIOGEN INC. (BIIB) reported Non Peo Neo Avg Total Comp Amt of $5.87 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-28.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-28
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $5.87M DEF 14A · filed 2026-04-28 |
| 2024-12-31 | $6.37M DEF 14A · filed 2026-04-28 |
| 2023-12-31 | $6.26M DEF 14A · filed 2026-04-28 |
| 2022-12-31 | $5.88M DEF 14A · filed 2026-04-28 |
| 2021-12-31 | $5.76M DEF 14A · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |